Biotech and Pharmaceutical
News & Jobs
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel
Immunomedics, Inc. (NQ: IMMU)
4.150 USD  -0.420 (-9.19%)
Official Closing Price  /  Updated: 8:10 PM EDT, Apr 23, 2014  /  Add to My Watchlist      
(IMMU) Community Analysis from
April 23, 2014
(Blogging Stocks, 8/27/09)
Filed under: Citigroup Inc. (C), Altria Group (MO), Boeing Co (BA), Amer Intl Group (AIG), Harley-Davidson (HOG) This morning's revised GDP and still high jobless claims were of no concern to the...(read more)
Immunomedics (IMMU) Company Overview

Image:Toplogo_3_770.gif‎ Immunomedics, Inc. (NASDAQ:IMMU) is a small biopharmaceutical company that develops treatments for cancer, Lupus, and other autoimmune diseases. Its drugs are all in their development stages and the Company has yet to come up with a drug it can sell. Without drug sales, it had a negative net profit in 2007 due to spending $19,841,000 on research. [1] In 2006, Immunomedics (IMMU) and UCB (a large, Belgian pharmaceuticals firm) entered a collaboration to fund, produce, and market Immunomedics' lead product, Epratuzumab, a new drug for use in treating cancer and autoimmune diseases like Lupus. [2] Through the collaboration, UCB became the primary means of funding Immunomedics' research, giving UCB control over segments of IMMU's business, such as running trials. [3] The company faces the challenge of controlling its projects while appeasing fund-contributing companies.

Immunomedics has a smaller amount of capital, with less funding, less marketing, and less ability to obtain approval from the government for testing and manufacturing in comparison to other drug companies. [4] Before it starts selling drugs in the US, the Company has to find means of finishing research, getting approved by the FDA, and competing against more powerful pharmaceuticals. However, it claims to have the next generation of therapeutic drugs for cancer and lupus patients; once approved, the effectiveness of these drugs will be the primary factor driving sales.

(Read more at Wikinvest )

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here